Kathleen M Haskell

US Patent:

20060142178, Jun 29, 2006

Filed:

Apr 4, 2003

Appl. No.:

10/510068

Inventors:

Stanley Barnett - North Wales PA, US
Deborah DeFeo-Jones - Lansdale PA, US
George Hartman - Lansdale PA, US
Kathleen Haskell - Colmar PA, US
Hans Huber - Lansdale PA, US
Craig Lindsley - Schwenksville PA, US
Zhijian Zhao - Wilmington DE, US

International Classification:

A61K 38/00
A61K 31/415

US Classification:

514002000, 514332000, 514406000

Abstract:

The present invention is directed to a method of treating cancer which comprises administration of a compound which selectively inhibits the activity of one or two of the isoforms of Akt, a serine/threonine protein kinase. The invention is particularly directed to the method wherein the compound is dependent on the presence of the pleckstrin homology domain of Akt for its inhibitory activity.

US Patent:

20100041666, Feb 18, 2010

Filed:

Oct 22, 2009

Appl. No.:

12/603927

Inventors:

Stanley F. Barnett - North Wales PA, US
Deborah DeFeo-Jones - Lansdale PA, US
Kathleen M. Haskell - Colmar PA, US
Hans E. Huber - Lansdale PA, US
Deborah D. Nahas - Perkasie PA, US

International Classification:

A61K 31/496
A61P 35/00

US Classification:

51425218

Abstract:

Use of the N-phenyl-2-pyrimidine-amine derivatives of formula I,in which the symbols and substituents have the meaning as given herein in free form or in pharmaceutically acceptable salt form in the manufacture of a pharmaceutical composition for the treatment of anergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis or mastocytosis;

US Patent:

20040106540, Jun 3, 2004

Filed:

Oct 2, 2003

Appl. No.:

10/473791

Inventors:

Stanley Barnett - North Wales PA, US
Deborah DeFeo-Jones - Lansdale PA, US
Kathleen Haskell - Colmar PA, US
Hans Huber - Lansdale PA, US
Deborah Nahas - Perkasie PA, US

International Classification:

A61K038/00

US Classification:

514/002000

Abstract:

The present invention is directed to a method of treating cancer which comprises administration of a compound which selectively inhibits the activity of one or two of the isoforms of Akt, a serine/threonine protein kinase. The invention is particularly directed to the method wherein the compound is dependent on the presence of the plestrin homology domain of Akt for its inhibitory activity.